If the unimpressive early performance of Cytos Biotechnology's anti-nicotine "vaccine" is any indication, we may not have to face the Orwellian possibilities of such drug use preventatives anytime soon. In Phase II clinical trials, Earth Times reports, 40 percent of subjects receiving the vaccine—which is supposed to stimulate production of antibodies that bind with nicotine molecules, making them too large to pass the blood-brain barrier—"were able to quit smoking for nearly six months." By comparison, 31 percent of the subjects who received the placebo "were able to stop smoking for 24 weeks"—i.e., nearly six months. Granted, these trials are intended mainly to demonstrate safety, but an effectiveness only slightly better than that of a placebo does not match the hopes of drug warriors who dream of taking their fight to our bloodstreams, although it may be enough to win FDA approval.
Notice, too, how the lead researcher misrepresents the way the vaccine is designed to work. He says smokers who receive it "don't feel that they have to take a cigarette to feel better," implying that the product somehow eliminates their cravings. But even if it were 100 percent effective, it would not make the cravings go away; it would just make it impossible to satisfy them.